Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Lisa D Eli"'
Autor:
Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102073- (2024)
Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible
Externí odkaz:
https://doaj.org/article/80c2e8e9bf2e4172bafb263c57f5769f
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea
Externí odkaz:
https://doaj.org/article/cf5037433d854254a48613d85af66f77
Publikováno v:
Cancer Research. 83:P6-12
Introduction: NER is a pan-HER tyrosine kinase inhibitor (TKI) approved for the treatment of HER2+ BC in the adjuvant setting following trastuzumab and in combination with capecitabine for advanced disease. Resistance to small molecule TKIs like NER
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Overall sequencing CONSORT diagram. Flow diagram of study patients and analyzed biospecimens processed through and selected for central sequencing using MSK-IMPACT and Guardant360. cfDNA, cell-free DNA; FFPE, formalin-fixed paraffin-embedded; MSK-IMP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadd31b50eb28b778540b40ef3547376
https://doi.org/10.1158/2159-8290.22535392.v1
https://doi.org/10.1158/2159-8290.22535392.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df3c52be345cb95e67d14e31497f606f
https://doi.org/10.1158/2159-8290.c.6547849.v1
https://doi.org/10.1158/2159-8290.c.6547849.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9a66139c86c7fc9c7963ce2aff13cc
https://doi.org/10.1158/2159-8290.22535398
https://doi.org/10.1158/2159-8290.22535398
Autor:
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
Publikováno v:
Biomedicines, Vol 9, Iss 7, p 740 (2021)
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identi
Externí odkaz:
https://doaj.org/article/cedd88ae516042b3b4bd35ba6d3e15c2
Autor:
Monica Arnedos, Christine M. Micheel, Fei Ye, Alshad S. Lalani, Grace Mann, Feng Xu, Lisa D. Eli, Mia Levy, Chetna Wathoo, Celeste Yu, Semih Dogan, Lillian Smyth, Fabrice Andre, Eva M. Lepisto, Deborah Schrag, Rinaa S. Punglia, Funda Meric-Bernstam, Philippe L. Bedard, Natalie Blauvelt, David M. Hyman, Thomas Stricker, Sheau-Chiann Chen, Michele L. LeNoue-Newton
Purpose:We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor–positive advanced breast cancer tumors harboring an ERBB2 mutation in the absence of a HER2 amplification.Experimental Design:We retrospectively col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ec427650dcc5bc448d1c3065e6084a
https://doi.org/10.1158/1078-0432.c.6531065.v1
https://doi.org/10.1158/1078-0432.c.6531065.v1
Autor:
Monica Arnedos, Christine M. Micheel, Fei Ye, Alshad S. Lalani, Grace Mann, Feng Xu, Lisa D. Eli, Mia Levy, Chetna Wathoo, Celeste Yu, Semih Dogan, Lillian Smyth, Fabrice Andre, Eva M. Lepisto, Deborah Schrag, Rinaa S. Punglia, Funda Meric-Bernstam, Philippe L. Bedard, Natalie Blauvelt, David M. Hyman, Thomas Stricker, Sheau-Chiann Chen, Michele L. LeNoue-Newton
Supplementary Figure from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c3e2dd1376d9df39a7eb6d780fea16
https://doi.org/10.1158/1078-0432.22483082
https://doi.org/10.1158/1078-0432.22483082